PR Newswire

An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States

Website

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States, according to surveyed U.S. and European neurologists.

» Read More